ROSSINI, DANIELE
 Distribuzione geografica
Continente #
NA - Nord America 252
EU - Europa 95
AS - Asia 25
AF - Africa 8
SA - Sud America 7
Totale 387
Nazione #
US - Stati Uniti d'America 250
IT - Italia 70
FR - Francia 11
PS - Palestinian Territory 10
DE - Germania 5
VN - Vietnam 5
IN - India 4
BR - Brasile 3
DZ - Algeria 3
RO - Romania 3
UG - Uganda 3
CA - Canada 2
CO - Colombia 2
EC - Ecuador 2
JP - Giappone 2
SG - Singapore 2
ZA - Sudafrica 2
CH - Svizzera 1
CN - Cina 1
ES - Italia 1
GB - Regno Unito 1
MY - Malesia 1
PT - Portogallo 1
SI - Slovenia 1
UA - Ucraina 1
Totale 387
Città #
Chicago 21
Seattle 18
Ashburn 16
Fairfield 16
Woodbridge 16
Buffalo 15
Houston 11
Rome 11
Santa Cruz 10
Cambridge 8
Wilmington 8
Herndon 6
Los Angeles 6
San Francisco 5
Serra 5
University Park 5
Ann Arbor 4
Bellevue 3
Dallas 3
Henderson 3
Las Vegas 3
Milan 3
Palermo 3
Pisa 3
Providence 3
Berlin 2
Cheyenne 2
Clearwater 2
Dong Ket 2
Hacienda Ibarra 2
Montefalco 2
Muizenberg 2
Mumbai 2
New York 2
Phoenix 2
Rochester 2
Sanluri 2
Verona 2
Yellow Springs 2
Asahikawa 1
Augusta 1
Bari 1
Bergamo 1
Boardman 1
Brindisi 1
Busto Arsizio 1
Béjaïa 1
Campina Grande 1
Castelpoto 1
Catania 1
Des Moines 1
Easton 1
Faro 1
Flensburg 1
Frankfurt Am Main 1
Hanoi 1
Jacksonville 1
Kolkata 1
Kumar 1
London 1
Milpitas 1
Nagano 1
Ottawa 1
Palma Campania 1
Paris 1
Parlin 1
Pasadena 1
Polcenigo 1
Portland 1
Potomac 1
Riva 1
Salt Lake City 1
San Diego 1
San Giorgio del Sannio 1
San Jose 1
Singapore 1
Torino 1
Toronto 1
Trieste 1
Valeggio sul Mincio 1
Wuhan 1
Totale 275
Nome #
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer, file e0d6c92c-198b-fcf8-e053-d805fe0aa794 195
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients, file e0d6c928-e94d-fcf8-e053-d805fe0aa794 162
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies, file e0d6c931-b004-fcf8-e053-d805fe0aa794 26
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study, file e0d6c92f-bed6-fcf8-e053-d805fe0aa794 7
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer, file e0d6c92c-d5ee-fcf8-e053-d805fe0aa794 3
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies, file e0d6c930-f2c0-fcf8-e053-d805fe0aa794 3
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial, file e0d6c92b-4fcb-fcf8-e053-d805fe0aa794 2
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study, file e0d6c92c-0d56-fcf8-e053-d805fe0aa794 2
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials, file e0d6c92f-8490-fcf8-e053-d805fe0aa794 2
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO, file e0d6c92f-97c3-fcf8-e053-d805fe0aa794 2
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer, file e0d6c930-c440-fcf8-e053-d805fe0aa794 2
Totale 406
Categoria #
all - tutte 751
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 751


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201917 0 0 0 0 0 0 0 0 0 3 7 7
2019/202066 3 4 0 3 12 7 7 8 8 5 4 5
2020/202186 11 18 6 4 7 12 3 4 7 2 5 7
2021/202257 3 4 5 1 12 4 1 5 2 3 12 5
2022/2023143 0 2 15 16 18 7 4 26 37 2 16 0
2023/202431 0 0 4 6 5 5 4 5 2 0 0 0
Totale 406